Sanofi India LimitedSANOFICorporate

Pharmaceuticals - Multinational Latest results: Dec 2024 7 quarters of data

₹2,942.10

MCap ₹6,776 Cr · P/E 16.4

Sanofi India Limited — Stock analysis & AI research Sanofi India Limited — Seasonality — best & worst months Sanofi India Limited — Technical indicators & charts Sanofi India Limited — Technical setup — score, trend, support & resistance Sanofi India Limited — Descending Channel pattern forming Sanofi India Limited — Live exchange announcements

📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📈 Multi-Timeframe Bearish Stocks 📈 Stocks Near 52-Week Low 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹515 Cr

Sales · Dec 2024

+9.8% YoY

₹118 Cr

Operating Profit · Dec 2024

+18.0% YoY

22.9%

OPM % · Dec 2024

+7.5% YoY

₹91 Cr

Net Profit · Dec 2024

-34.1% YoY

₹39.70

EPS · Dec 2024

-33.7% YoY

📝 Sanofi India Limited — results explained

Quarter ended December 2024 (Q3 FY25)

Sanofi India Limited reported revenue of ₹515 crore for the quarter ended December 2024 (Q3 FY25), up 9.8% from ₹469 crore in the same quarter last year, and down 1.7% sequentially over the September 2024 quarter.

Net profit fell 34.1% year-on-year to ₹91 crore, from ₹138 crore. Earnings per share (EPS) came in at ₹39.70.

Operating profit stood at ₹118 crore — an operating margin (OPM) of 22.9%, compared with 21.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY25, Sanofi India Limited posted revenue of ₹1,502 crore, a decline of 83.4% over FY24, with a net profit of ₹276 crore (down 85.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,235 crore with a net profit of ₹413 crore.

Valuation snapshot

At the current price of ₹2,942.10, SANOFI has a market capitalisation of ₹6,776 crore and a trailing P/E of about 16.4.

Within the Pharmaceuticals - Multinational industry, it is the 3rd-largest of the 3 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 60.40%, foreign institutional investors (FIIs) 5.69%, domestic institutional investors (DIIs) 19.87%, public shareholders 14.04% of Sanofi India Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹6,776 Cr

Current Price ?

₹2,942.1

P/E ?

16.41below ind

Industry P/E ?

24.10

P/B ?

N/A

P/S ?

3.03

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

6.1%

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

₹2,235 Cr

OPM ?

25.6%

Profit after tax (TTM) ?

₹413 Cr

EPS (TTM) ?

₹179.33

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹515 Cr

PAT — latest qtr ?

₹91 Cr

YoY qtr sales growth ?

9.8%

YoY qtr profit growth ?

-34.1%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

N/A

Debt to Equity ?

N/A

Interest Coverage ?

406.7

Current Ratio ?

N/A

Ownership

Promoter holding ?

60.40%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-13.8%

Return 6 months ?

-17.4%

🗓️ Quarterly results (7 quarters · ₹ Cr)

same fiscal quarter as Dec bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	YoY %	QoQ %
Sales	706	7,146	469	732	464	524	515	+9.8%	-1.7%
Operating Profit	178	2,082	100	219	116	120	118	+18.0%	-1.4%
Other Income	16	118	77	6	5	2	14	-81.8%	+508.7%
Interest	1	3	0	0	0	0	0	—	-100.0%
Depreciation	10	99	9	10	9	9	10	+11.1%	+11.1%
Profit Before Tax	183	2,098	167	188	139	113	122	-26.9%	+8.3%
Net Profit	123	1,519	138	137	103	82	91	-34.1%	+10.7%
EPS	53.37	65.95	59.87	59.31	44.81	35.69	39.70	-33.7%	+11.2%
OPM %	25.2%	29.1%	21.3%	29.9%	25.0%	22.8%	22.9%	+7.5%	+0.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY24	FY25	TTM	YoY %
Sales	₹9,054 Cr	₹1,502 Cr	₹2,235 Cr	-83.4%
Operating Profit	₹2,579 Cr	₹353 Cr	₹572 Cr	-86.3%
OPM %	28.49%	23.52%	25.61%	-17.4%
NPM %	21.17%	18.40%	18.48%	-13.1%
Other Income	₹217 Cr	₹21 Cr	₹28 Cr	-90.3%
Depreciation	₹128 Cr	₹28 Cr	₹38 Cr	-78.1%
Interest	₹4 Cr	₹1 Cr	₹1 Cr	-80.0%
EBIT	₹2,451 Cr	₹325 Cr	₹534 Cr	-86.7%
PBT	₹2,637 Cr	₹374 Cr	₹562 Cr	-85.8%
Tax	₹691 Cr	₹66 Cr	₹118 Cr	-90.4%
Net Profit	₹1,916 Cr	₹276 Cr	₹413 Cr	-85.6%
EPS	₹238.50	₹120.20	₹179.51	-49.6%
Material Cost	₹5,789 Cr	₹470 Cr	₹654 Cr	-91.9%
Employee Cost	₹1,118 Cr	₹117 Cr	₹209 Cr	-89.5%
Extraordinary Items	₹-27 Cr	₹-19 Cr	₹-46 Cr	+28.8%

👥 Shareholding (latest 1 periods)

Metric	Jun 2026	% Chg
Promoters	60.40%	—
FIIs	5.69%	—
DIIs	19.87%	—
Public	14.04%	—
No. of Shareholders	80,005	—

⚖️ Peer comparison

Industry: Pharmaceuticals - Multinational · 3 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	PGHL Procter & Gamble	₹5,321.00	8,833	24.7	1,433	358	32.5%	25.0%	15.6%	30.8%	7.3%	45.7%
2	SANOFICONR Sanofi Consumer	₹3,650.00	8,418	31.6	950	266	37.2%	28.0%	—	—	6.7%	12.8%
3	SANOFI Sanofi India	₹2,928.60	6,745	20.8	1,805	324	26.7%	18.0%	16.4%	1.8%	7.8%	19.3%

❓ Frequently asked questions

What was Sanofi India Limited's revenue in Q3 FY25?

What was Sanofi India Limited's net profit in Q3 FY25?